Absent extraordinary circumstances, the Patent Trial and Appeal Board “should never cancel claims it has not determined to be unpatentable as a sanction” for misconduct during a board proceeding, ...

While Americans understand the benefits of GLP-1 agonist medications, 83% of Americans are unwilling to pay more than $100 in ...

By triggering weight loss using the likes of Ozempic, people can expect various possible changes to their appearance ...

Investing.com -- Parvus Asset Management, a London-based activist hedge fund, is acquiring a stake in Danish pharmaceutical company Novo Nordisk (NYSE: NVO ), according to The Financial Times. The ...

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

S&P 500, Eli Lilly and Company, Novo Nordisk A/S Class B, Novo Nordisk A/S. Read 's Market Analysis on Investing.com ...

In the UK, anxiety, panic attacks and insomnia are not listed as possible side-effects for Ozempic, Wegovy or Mounjaro.

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s ...

Discover a new, science-backed way to classify ultra-processed foods. Learn how the WISEcode system offers a more nuanced ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

Since its launch in late March, Mounjaro sales have trebled. Winselow Tucker, president and general manager of Lilly in India ...

The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...